Indications & Availability
Products may have different labeling in different countries.
United States
Indication
TheraSphere® is indicated for radiation treatment or as a neoadjuvant to surgery or transplantation in patients with unresectable HCC who can have placement of appropriately positioned hepatic arterial catheters. The device is also indicated for HCC patients with partial or branch portal vein thrombosis/occlusion, when clinical evaluation warrants the treatment.
Please refer to the TheraSphere® Yttrium 90 Glass Microspheres US Package Insert for additional information:
Availability
TheraSphere® is currently approved by the US FDA for use as a Humanitarian Device and is being used at a number of clinical centers in the United States. Find a Treatment Center near you .
For information on obtaining TheraSphere® for use in your facility please call Nordion at +1 866 363 3330 or email therasphere@nordion.com. Nordion will ship to facilities with the appropriate radioactive materials license and assurance of IRB approval.
